COVID-19 in persons with chronic myeloid leukaemia
Fecha
2020-05-18Autor
Li, Weiming
Wang, Danyu
Guo, Jingming
Yuan, Guolin
Yang, Zhuangzhi
Gale, Robert Peter
You, Yong
Chen, Zhichao
Chen, Shiming
Wan, Chucheng
Zhu, Xiaojian
Chang, Wei
Sheng, Lingshuang
Cheng, Hui
Zhang, Youshan
Li, Qing
Qin, Jun
Hubei Anti-Cancer Association
Meng, Li
Jiang, Qian
Documentos PDF
Resumen en idioma extranjero
We studied by questionnaire 530 subjects with chronic myeloid leukaemia (CML) in Hubei Province during the recent SARS-CoV-2 epidemic. Five developed confirmed (N = 4) or probable COVID-19 (N = 1). Prevalence of COVID-19 in our subjects, 0.9% (95% Confidence Interval, 0.1, 1.8%) was ninefold higher than 0.1% (0, 0.12%) reported in normals but lower than 10% (6, 17%) reported in hospitalised persons with other haematological cancers or normal health-care providers, 7% (4, 12%). Co-variates associated with an increased risk of developing COVID-19 amongst persons with CML were exposure to someone infected with SARS-CoV-2 (P = 0.037), no complete haematologic response (P = 0.003) and co-morbidity(ies) (P = 0.024). There was also an increased risk of developing COVID-19 in subjects in advanced phase CML (P = 0.004) even when they achieved a complete cytogenetic response or major molecular response at the time of exposure to SARS-CoV-2. 1 of 21 subjects receiving 3rd generation tyrosine kinase-inhibitor (TKI) developed COVID-19 versus 3 of 346 subjects receiving imatinib versus 0 of 162 subjects receiving 2nd generation TKIs (P = 0.096). Other co-variates such as age and TKI-therapy duration were not significantly associated with an increased risk of developing COVID-19. Persons with these risk factors may benefit from increased surveillance of SARS-CoV-2 infection and possible protective isolation.
Palabras clave
chronic myeloid leukaemia; leukaemiaEnlace al recurso
https://www.nature.com/articles/s41375-020-0853-6Colecciones
Estadísticas Google Analytics
Comentarios
Respuesta Comentario Repositorio Expeditio
Gracias por tomarse el tiempo para darnos su opinión.